IL17A and neoplasm: We identify several Th17–Treg transdifferentiation-associated transmembrane molecules on IL-17A+Foxp3+ cells that may be feasible targets to manipulate Treg cell-associated tumour immune surveillance, and complement programmed cell death protein 1 (PD1)-mediated control of T-cell activation.